icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
A3qSJgWz4NJR3uVt